يعرض 1 - 10 نتائج من 33 نتيجة بحث عن '"Lu, DaoPei"', وقت الاستعلام: 0.74s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    Patent
  5. 5
    دورية أكاديمية

    المساهمون: Chen, H (reprint author), Acad Mil Med Sci, Affiliated Hosp, Dept Hematopoiet Stem Cell Transplantat, Beijing, Peoples R China., Lu, DP (reprint author), Hebei Yanda Ludaopei Hosp, Langfang, Hebei, Peoples R China., Acad Mil Med Sci, Affiliated Hosp, Dept Hematopoiet Stem Cell Transplantat, Beijing, Peoples R China., Hebei Yanda Ludaopei Hosp, Langfang, Hebei, Peoples R China., Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Hebei, Peoples R China., Peking Univ, Peoples Hosp, Beijing, Peoples R China., Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China., Shanghai Childrens Med Ctr, Shanghai, Peoples R China., Soochow Univ, Affiliated Hosp 1, Suzhou, Zhejiang, Peoples R China., Changhai Hosp Shanghai, Shanghai, Peoples R China., Shang Hai Gen Hosp, Shanghai, Peoples R China., Chinese Acad Med Sci, Inst Hematol & Hosp Blood Dis, Tianjin, Peoples R China., Peking Union Med Coll, Tianjin, Peoples R China.

    المصدر: SCI

    العلاقة: ANNALS OF TRANSPLANTATION.2017,22,384-401.; 1906816; http://hdl.handle.net/20.500.11897/472644Test; WOS:000404632700001

  6. 6
    تقرير
  7. 7
    تقرير
  8. 8
    تقرير
  9. 9
    تقرير
  10. 10
    تقرير

    المساهمون: Daihong Liu, Director

    المصدر: Kuzma Z, Eder S, Bohm A, Pernka E, Vormtag L, Kalhs P, Petkov V, Stary G, Nepp J, Knobler R, Just U, Krenn K, Worel N, Gre HT. Snantly worse surval of patnts wh N-defed chron graft-versus-host dease and thrombocytopen or progresse onset type: results of a prospecte study. Leukem. 2012 Apr;26(4):746-56. do 10.1038/leu.2011.257. Epub 2011 Sep 16.
    Thepot S, Zhou J, Perrot A, Rob M, Xhaard A, de Latour RP, Ades L, Raud P, Petropoulou AD, Porcher R, Soc G. The graft-versus-leukem effect maly restrted to N-defed chron graft-versus-host dease after reduced tensy condng before allogene stem cell transplantatn. Leukem. 2010 Nov;24(11):1852-8. do 10.1038/leu.2010.187. Epub 2010 Sep 9.
    Leve JE, Braun TM, Harr AC, Holler E, Taylor A, Mler H, Magenau J, Wedorf DJ, Ho VT, Bolanos-Meade J, AlousAM, Ferrara JL; Blood and Marrow Transplant Clal Trls Network. A prognost score for acute graft-versus-host dease based on bmarkers: a multentre study. Lancet Haematol. 2015 Jan;2(1):e21-9. do 10.1016/S2352-3026(14)00035-0. Epub 2014 Dec 23.
    Major-Monfrd H, Renter AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wolfl M, Qayed M, Hexner EO, Wudharn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Az M, Etra A, Yan GA, Kroger N, Weber D, Chen YB, Nakamura R, Rosler W, Kko CL, Harr AC, Pulsher M, Reshef R, Kowalyk S, Morales G, Torres Ozbek U, Ferrara JLM, Leve JE. MAG bmarkers predt long-term outcomes for stero-restant acute GVHD. Blood. 2018 Jun 21;131(25):2846-2855. do 10.1182/blood-2018-01-822957. Epub 2018 Mar 15.
    von Bubnoff N, orst G, Grha O, Rothlg N, Bertz H, Duyster J, Fke J, Zeer R. Ruxol GvHD (R) study: a multenter, randomed phase 2 trl to determe the response rate of Ruxol and best avaable treatment (BAT) versus BAT stero-refractory acute graft-versus-host dease (aGvHD) (NCT02396628). BMC Cancer. 2018 Nov 19;18(1):1132. do 10.1186/s12885-018-5045-7.
    Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host Disease